PPARA and primary biliary cholangitis: Moreover, a variety of new agents, acting with different mechanisms of action, are under clinical evaluations for PBC treatment, e.g., PPAR agonists, NOX inhibitors, immunomodulators, and mesenchymal stem cells transplantation.